Here are the 424B prospectus supplements from Aptevo Therapeutics Inc (APVO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow APVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APVO filings page.
Aptevo Therapeutics Inc. (APVO) may offer and sell additional common stock with an aggregate offering price of up to $2,309,834 from time to time through Roth Capital Partners as sales agent under its at-the-market agreement. The amount is subject to Form S-3’s limit of one-third of Public Float in any 12-month period while Public Float remains below $75,000,000.
Public Float as of October 30, 2026 was $6,929,502, based on 2,665,193 shares of common stock issued and outstanding and held by non-affiliates on that date, and a share price of $2.60 as of September 2, 2026. Aptevo reported 303,157 shares sold under the Sales Agreement and Prior Prospectus for aggregate gross sale proceeds of $11,799,276. It also reported $0 of securities sold under General Instruction I.B.6 during the prior 12-month period. If Public Float increases enough to permit a greater amount of sales, Aptevo says it will file another prospectus supplement before making those sales.
Aptevo Therapeutics Inc. (APVO) is registering up to 6,444,858 shares of common stock for resale by existing investors, all issuable upon the exercise of pre-funded warrants, common warrants and inducement warrants. These are secondary sales by selling stockholders; Aptevo will not receive proceeds from their resale.
As context, Aptevo had 1,810,215 shares outstanding as of August 21, 2026, so the registered warrant shares are large relative to current equity. The warrants generally cannot be exercised above 4.99% or 9.99% beneficial ownership caps. APVO remains listed on Nasdaq, with a reported share price of $2.60 on September 2, 2026, but discloses risks around equity dilution and potential future Nasdaq listing deficiencies, including stockholders’ equity, bid-price and market-value-of-listed-securities requirements.
Aptevo Therapeutics Inc. is registering up to 7,075,471 shares of common stock for resale by YA II PN, LTD. under a $60.0 million standby equity purchase agreement. These shares will be issued over time at Aptevo’s discretion during a multi‑year commitment period.
Aptevo will not receive proceeds from YA’s resale of the registered shares, but may raise up to $60.0 million in gross proceeds from selling “Advance Shares” to YA at a price equal to 96% of the lowest of three daily VWAPs during each pricing period. As of September 30, 2025, Aptevo had 767,164 common shares outstanding, and an ownership limitation of 9.99% and an exchange cap of approximately 19.99% apply to issuances under the agreement.
Aptevo Therapeutics Inc. is registering up to 6,903,755 shares of common stock for resale by YA II PN, LTD. under a standby equity purchase agreement. These shares relate to an up to $25.0 million equity line Aptevo entered into with YA on June 16, 2025, under which YA buys shares from Aptevo at 96% of the lowest three-day VWAP during each pricing period. Aptevo will not receive any proceeds from YA’s resale of these shares.
As of September 30, 2025, Aptevo had 13,808,966 shares outstanding, and if all registered shares are issued, total shares outstanding would rise to 20,712,721. The company has already raised approximately $15.0 million under a prior registration and expects to use any additional proceeds from future sales to YA for pipeline development, new programs, business development, and general corporate purposes. The structure may lead to substantial dilution and stock price volatility, and the filing details Nasdaq listing and going-concern related risks.